Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03900884
Title Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (PALVEN)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia

estrogen-receptor positive breast cancer


Letrozole + Palbociclib + Venetoclax

Age Groups: adult | senior
Covered Countries

No variant requirements are available.